This multicenter randomized control study with placebo was designed to determine the risks and benefits of double antiaggregation for longer than 12 months post DES stenting.
9961 patients were randomized to continue on placebo or thienopyridine after 12 months. Thienopyridine reduces the incidence of in-stent thrombosis (0.4% vs 1.4%; p<0,001) and cardiovascular events (4.3% vs 5.9%; p<0.001).
AMI rates were also lower after 12 months (2.1% vs 4.1%; p<0,001) compared to bleeding rates that, as expected, resulted higher (2.5% vs 1.6%, p=0,001).
Conclusion
Double antiaggregation longer than 12 months after DES stenting reduces in-stent thrombosis and cardiovascular events but increases bleeding risk.
Laura Mauri
2014-11-17
Original title: Risk and Benefit of Prolonged Dual Antiplatelet Therapy After Drug-eluting Coronary Stents: Primary Endpoint Results from the Dual Antiplatelet Therapy Study.
